United States Trichomoniasis Drug Market Size & Outlook, 2026-2034


United States Trichomoniasis Drug Market Insights

  • Based on Reed Intelligence findings, the United States Trichomoniasis Drug Market reached USD 253.82 Million in 2025 and is estimated to attain USD 435.13 Million by 2034.
  • From 2026 to 2034, the United States market is expected to grow at a steady CAGR of 6.2%.
  • Within the Drug Class category, Nitroimidazoles dominated in 2025 in terms of market size contribution.
  • Over the forecast period, Combination Therapies is forecasted to deliver the fastest growth, positioning it as the most lucrative Drug Class segment.

Other Key Findings


  • In 2025, United States accounted for 30.95% of the global Trichomoniasis Drug Market size.
  • By 2034, United States is expected to lead the global Trichomoniasis Drug Market in terms of market size.
  • Within North America, United States is projected to dominate the regional Trichomoniasis Drug Market size by 2034.
  • Canada is identified as the fastest-growing market in North America, anticipated to reach USD 118.25 Million by 2034.

Report Summary

Report Scope Details
Base Year for Study 2025
Study Period 2022-2034
Historical Period 2022-2024
Forecast Period 2026-2034
Market Size In 2025 USD 253.82 Million
Market Size In 2034 USD 435.13 Million
Largest segment Nitroimidazoles
Units Revenue in USD Million
CAGR 6.2% (2026-2034)
Segmnetation Covered
Drug Class
  1. Nitroimidazoles
  2. Combination Therapies
  3. Others
Route of Administration
  1. Oral
  2. Topical
  3. Injectable
Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
Patient Demographics
  1. Adult Women
  2. Adult Men
  3. Adolescents
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Related Reports